TORONTO, Dec. 2, 2022 /PRNewswire-PRWeb/ -- To develop the next generation of targeted cancer therapies, researchers need cancer models that can stand in as true proxies for human disease. Traditional research models commonly used in commercial applications have a place in screening and can provide directional information about potential therapeutic responses. However, they do not replicate the heterogenous biology and complex network of dysregulated pathways that characterize real-life human tumors. In fact, most models used in preclinical drug development fail to address the importance of tumor microenvironment, despite its well-established role in druggability and immune response. Translational research in oncology can greatly benefit from improvements to these models.
- Translational research in oncology can greatly benefit from improvements to these models.
- Translational research success is largely dependent upon selecting or sometimes custom-developing the most appropriate preclinical model to assess a candidate's therapeutic response.
- Register to learn about the innovations in preclinical model development for translational research in oncology.
- For more information, or to register for this event, visit Translational Research in Oncology Innovations in Model Development .